PROLOR Biotech, Inc. (PBTH: Quote) said Thursday that it plans to offer and sell shares of its common stock in an underwritten public offering.
The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
PROLOR said it plans to use the net proceeds from the offering for general corporate purposes, which may include research and development expenses, including expenses related to clinical trials, capital expenditures, working capital, and general and administrative expenses. PROLOR may also use a portion of the net proceeds to acquire or invest in complementary businesses, products and technologies.
Click here to receive FREE breaking news email alerts for PROLOR Biotech, Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: firstname.lastname@example.org